May 16, 2025 01:58AM Elevation Oncology, Inc. (ELEV) Misses Q1 EPS by 4c

Apr 25, 2025 01:01PM Elevation Oncology (ELEV) Presents Preclinical Proof-of-Concept Data for EO-1022

Mar 21, 2025 03:43AM Piper Sandler Downgrades Elevation Oncology (ELEV) to Neutral

Mar 21, 2025 03:42AM Citizens JMP Downgrades Elevation Oncology (ELEV) to Market Perform

Mar 20, 2025 08:01AM Elevation Oncology (ELEV) to Discontinue Development of EO-3021

Mar 20, 2025 07:55AM Elevation Oncology (ELEV) Halted, News Pending

Mar 10, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Elevation Oncology (ELEV)

Mar 10, 2025 04:19AM Citizens JMP Reiterates Market Outperform Rating on Elevation Oncology (ELEV)

Mar 6, 2025 04:51PM Elevation Oncology, Inc. (ELEV) Tops Q4 EPS by 4c

Jan 13, 2025 07:32AM Elevation Oncology (ELEV) Provides Updates on Differentiated ADC Programs and Upcoming Milestones

Dec 12, 2024 07:33AM Elevation Oncology (ELEV) Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Dec 5, 2024 07:31AM Elevation Oncology (ELEV) Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors

Sep 23, 2024 07:30AM Elevation Oncology (ELEV) Receives Fast Track Designation from the FDA for EO-3021

Aug 6, 2024 01:51PM TD Cowen Reiterates Buy Rating on Elevation Oncology (ELEV)

Aug 6, 2024 09:02AM Elevation Oncology, Inc. (ELEV) Tops Q2 EPS by 4c

Aug 6, 2024 07:02AM Elevation Oncology (ELEV) Reports Promising Initial Data from Phase 1 Trial of EO-3021

Jun 28, 2024 10:38AM TD Cowen Reiterates Buy Rating on Elevation Oncology (ELEV)

Jun 28, 2024 08:20AM Piper Sandler Reiterates Overweight Rating on Elevation Oncology (ELEV)